{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:56:47Z","timestamp":1790708207032,"version":"4.1.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Hospitalizations are increasing in the US due to infections related to opioid use disorder (OUD); however, few patients have treatment with medications for OUD (MOUD) initiated. Injectable long-acting buprenorphine (LAB) could help improve MOUD receipt and infection treatment completion.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare initiation of LAB combined with infectious disease (ID) management (ID-LAB) with treatment as usual (TAU) during inpatient medical hospitalization periods for improving receipt of MOUD at 12 weeks.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (COMMIT) trial was a multisite randomized clinical trial with enrollment from August 19, 2020, through October 31, 2023, at 3 US hospital systems in Connecticut, Pennsylvania, and South Carolina. Eligible participants were individuals hospitalized with a diagnosis of moderate to severe OUD according to the Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic> (Fifth Edition) and concurrent infection. Intent-to-treat outcomes were assessed at the end of the 12-week intervention period.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants were randomized 1:1 to receive ID-LAB or TAU during treatment for infection in a hospital setting or early after discharge. All participants received a nurse care medical management intervention.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the proportion of patients who received any form of MOUD at 12 weeks after randomization. Models were adjusted by site, prescription of MOUD in the 30 days prior to hospitalization, and the baseline value of each outcome when assessable.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 171 participants who were enrolled, 86 were randomized to the ID-LAB arm and 85 to the TAU arm. A total of 88 participants (51.5%) were men, and median age was 39 (IQR, 33-47) years. At 12 weeks, there was no statistically significant difference in receipt of MOUD between the ID-LAB and TAU groups, with 51 patients (59.3%) and 46 (54.1%), respectively, receiving MOUD (adjusted rate ratio, 1.01; 95% CI, 0.78-1.30).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial comparing initiation of LAB for OUD with ID management in the hospital setting compared with TAU, there was no difference between arms in the receipt of MOUD at 12 weeks. The TAU arm had higher retention than anticipated. These findings suggest that hospitalization with an infection related to drug use may present an opportunity to identify OUD and initiate MOUD that may include injectable LAB. The nurse case management services provided to all participants should be evaluated in future studies.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04180020<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.13000","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T15:30:37Z","timestamp":1748619037000},"page":"e2513000","source":"Crossref","is-referenced-by-count":6,"title":["Initiating Injectable Buprenorphine in People Hospitalized With Infections"],"prefix":"10.1001","volume":"8","author":[{"given":"Nikhil","family":"Seval","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerana","family":"Roth","sequence":"additional","affiliation":[{"name":"Addiction Medicine Center, Prisma Health, Greenville, South Carolina"},{"name":"University of South Carolina School of Medicine Greenville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Frank","sequence":"additional","affiliation":[{"name":"Yale AIDS Program, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Di Paola","sequence":"additional","affiliation":[{"name":"Yale AIDS Program, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Litwin","sequence":"additional","affiliation":[{"name":"Addiction Medicine Center, Prisma Health, Greenville, South Carolina"},{"name":"University of South Carolina School of Medicine Greenville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Vander Wyk","sequence":"additional","affiliation":[{"name":"Yale AIDS Program, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Neirinckx","sequence":"additional","affiliation":[{"name":"Yale AIDS Program, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Schlossberg","sequence":"additional","affiliation":[{"name":"Yale AIDS Program, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lawson","sequence":"additional","affiliation":[{"name":"Addiction Medicine Center, Prisma Health, Greenville, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Strong","sequence":"additional","affiliation":[{"name":"Addiction Medicine Center, Prisma Health, Greenville, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith A.","family":"Schade","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Nunez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances R.","family":"Levin","sequence":"additional","affiliation":[{"name":"College of Physicians and Surgeons of Columbia University, New York, New York"},{"name":"The New York State Psychiatric Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen T.","family":"Brady","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[{"name":"College of Physicians and Surgeons of Columbia University, New York, New York"},{"name":"The New York State Psychiatric Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[{"name":"Yale AIDS Program, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"19","key":"zoi250430r2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012969","article-title":"Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016.","volume":"8","author":"Kadri","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"zoi250430r3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014.","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health"},{"issue":"8","key":"zoi250430r4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMp2204687","article-title":"Hospital standards of care for people with substance use disorder.","volume":"387","author":"Englander","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250430r5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"zoi250430r6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","volume":"2009","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"9776","key":"zoi250430r7","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"zoi250430r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021.","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi250430r9","article-title":"Infectious complications of addiction: a call for a new subspecialty within infectious diseases.","author":"Serota","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi250430r10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2020.2559","article-title":"Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the National Academies of Sciences, Engineering, and Medicine.","volume":"324","author":"Springer","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"zoi250430r11","doi-asserted-by":"publisher","first-page":"xiii","DOI":"10.1016\/j.idc.2020.06.016","article-title":"Addressing the intersection of infectious disease epidemics and opioid and substance use epidemics.","volume":"34","author":"Springer","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"zoi250430r12","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1093\/infdis\/jiz673","article-title":"Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA\u2019s advocacy agenda.","volume":"222","author":"Springer","year":"2020","journal-title":"J Infect Dis"},{"issue":"1","key":"zoi250430r13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz539","article-title":"Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases.","volume":"7","author":"Seval","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"10173","key":"zoi250430r14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"zoi250430r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106394","article-title":"Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder.","volume":"105","author":"Seval","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"zoi250430r17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS).","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"issue":"5920","key":"zoi250430r18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/bmj.2.5920.656","article-title":"Controlled sedation with alphaxalone-alphadolone.","volume":"2","author":"Ramsay","year":"1974","journal-title":"BMJ"},{"key":"zoi250430r19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in community health centers.","volume":"60","author":"LaBelle","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"zoi250430r20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.","volume":"171","author":"Alford","year":"2011","journal-title":"Arch Intern Med"},{"key":"zoi250430r23","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"zoi250430r24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"18","key":"zoi250430r25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study.","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"zoi250430r26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/jts.22059","article-title":"The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): development and initial psychometric evaluation.","volume":"28","author":"Blevins","year":"2015","journal-title":"J Trauma Stress"},{"issue":"2","key":"zoi250430r27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S0033291704002892","article-title":"The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population.","volume":"35","author":"Kessler","year":"2005","journal-title":"Psychol Med"},{"issue":"3","key":"zoi250430r28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment.","volume":"28","author":"The WHOQOL Group","year":"1998","journal-title":"Psychol Med"},{"issue":"6","key":"zoi250430r29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption\u2013II.","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"issue":"6","key":"zoi250430r30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s11606-009-0981-1","article-title":"Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference.","volume":"24","author":"Krebs","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"16","key":"zoi250430r32","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial.","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"zoi250430r33","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"19","key":"zoi250430r34","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What\u2019s the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes.","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"issue":"12","key":"zoi250430r35","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"zoi250430r36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"zoi250430r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.05.007","article-title":"Addiction consultation services\u2014linking hospitalized patients to outpatient addiction treatment.","volume":"79","author":"Trowbridge","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi250430r38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s13181-021-00858-z","article-title":"Methadone vs buprenorphine for in-hospital initiation: which is better for outpatient care retention in patients with opioid use disorder?","volume":"18","author":"Kessler","year":"2022","journal-title":"J Med Toxicol"},{"issue":"7","key":"zoi250430r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21740","article-title":"Medication for opioid use disorder after serious injection-related infections in Massachusetts.","volume":"7","author":"Kimmel","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi250430r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21640","article-title":"Serious opioid injection-related infection and initiation of medication for opioid use disorder.","volume":"7","author":"Springer","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi250430r41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamainternmed.2023.5701","article-title":"Nurse care management for opioid use disorder treatment: the PROUD cluster randomized clinical trial.","volume":"183","author":"Wartko","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi250430r42","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial.","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi250430r43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial.","volume":"78","author":"Springer","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"zoi250430r44","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1097\/ADM.0000000000001136","article-title":"Inpatient low-dose transitions from full agonist opioids including methadone onto long-acting depot buprenorphine: case series from a multicenter clinical trial.","volume":"17","author":"Seval","year":"2023","journal-title":"J Addict Med"},{"issue":"3","key":"zoi250430r45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/cid\/ciac714","article-title":"Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs.","volume":"76","author":"Wildenthal","year":"2023","journal-title":"Clin Infect Dis"},{"key":"zoi250430r46","doi-asserted-by":"publisher","first-page":"S772","DOI":"10.1093\/ofid\/ofz360.1933","article-title":"The use of dalbavancin for Staphylococcus aureus bacteremia in persons who inject drugs (PWID).","volume":"6","author":"Van Hise","year":"2255","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"zoi250430r48","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.cmi.2023.04.005","article-title":"Which trial do we need? long-acting glycopeptides versus oral antibiotics for infective endocarditis in patients with substance use disorder.","volume":"29","author":"Wurcel","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"zoi250430r49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22303","article-title":"Trends in opioid toxicity-related deaths in the US before and after the start of the COVID-19 pandemic, 2011-2021.","volume":"6","author":"Gomes","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi250430r16","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013","edition":"5th ed"},{"key":"zoi250430r21"},{"key":"zoi250430r22","author":"Sobell","year":"1992"},{"key":"zoi250430r1","unstructured":"Ahmad? FBCJ, Rossen? LM, Sutton? P. Provisional drug overdose death counts. National Vital Statistics System, National Center for Health Statistics, Centers for Disease Control and Prevention. Accessed November 1, 2024. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi250430r31","unstructured":"National Institute on Drug Abuse. Seek, test, treat and retain for vulnerable populations: data harmonization measure, HIV risk behaviors. Accessed January 3, 2021. https:\/\/www.drugabuse.gov\/sites\/default\/files\/HIV_Risk_BehaviorsV.pdf"},{"key":"zoi250430r47","unstructured":"SUBLOCADE. Package insert. 2025. Accessed March 1, 2025. https:\/\/www.sublocade.com\/Content\/pdf\/prescribing-information.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2834656\/seval_2025_oi_250430_1747842043.8058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T15:30:39Z","timestamp":1748619039000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2834656"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.13000","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}